115 related articles for article (PubMed ID: 2687858)
1. Inhibition of desipramine 2-hydroxylation by quinidine and quinine in rapid and slow debrisoquine hydroxylators.
Spina E; Steiner E; Dumont E; Dahlqvist R
Psychopharmacol Ser; 1989; 7():201-5. PubMed ID: 2687858
[No Abstract] [Full Text] [Related]
2. Inhibition of desipramine 2-hydroxylation by quinidine and quinine.
Steiner E; Dumont E; Spina E; Dahlqvist R
Clin Pharmacol Ther; 1988 May; 43(5):577-81. PubMed ID: 3365919
[TBL] [Abstract][Full Text] [Related]
3. Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment.
Brøsen K; Gram LF; Haghfelt T; Bertilsson L
Pharmacol Toxicol; 1987 Apr; 60(4):312-4. PubMed ID: 3588528
[TBL] [Abstract][Full Text] [Related]
4. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS
Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
[TBL] [Abstract][Full Text] [Related]
5. Hydroxylation of desmethylimipramine: dependence on the debrisoquin hydroxylation phenotype.
Spina E; Steiner E; Ericsson O; Sjöqvist F
Clin Pharmacol Ther; 1987 Mar; 41(3):314-9. PubMed ID: 3816019
[TBL] [Abstract][Full Text] [Related]
6. Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators.
Steiner E; Spina E
Clin Pharmacol Ther; 1987 Sep; 42(3):278-82. PubMed ID: 3621781
[TBL] [Abstract][Full Text] [Related]
7. Comparative effects of the diastereoisomers, quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers.
Ayesh R; Dawling S; Hayler A; Oates NS; Cholerton S; Widdop B; Idle JR; Smith RL
Chirality; 1991; 3(1):14-8. PubMed ID: 2039678
[TBL] [Abstract][Full Text] [Related]
8. Interethnic dissociation between debrisoquine and desipramine hydroxylation.
Rudorfer MV; Lane EA; Potter WZ
J Clin Psychopharmacol; 1985 Apr; 5(2):89-92. PubMed ID: 3988975
[TBL] [Abstract][Full Text] [Related]
9. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.
Otton SV; Crewe HK; Lennard MS; Tucker GT; Woods HF
J Pharmacol Exp Ther; 1988 Oct; 247(1):242-7. PubMed ID: 3171974
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes.
Spina E; Birgersson C; von Bahr C; Ericsson O; Mellström B; Steiner E; Sjöqvist F
Clin Pharmacol Ther; 1984 Nov; 36(5):677-82. PubMed ID: 6488689
[TBL] [Abstract][Full Text] [Related]
11. 4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine.
Granvil CP; Krausz KW; Gelboin HV; Idle JR; Gonzalez FJ
J Pharmacol Exp Ther; 2002 Jun; 301(3):1025-32. PubMed ID: 12023534
[TBL] [Abstract][Full Text] [Related]
12. The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man.
Kobayashi S; Murray S; Watson D; Sesardic D; Davies DS; Boobis AR
Biochem Pharmacol; 1989 Sep; 38(17):2795-9. PubMed ID: 2775304
[TBL] [Abstract][Full Text] [Related]
13. Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings.
Dahl-Puustinen ML; Lidén A; Alm C; Nordin C; Bertilsson L
Clin Pharmacol Ther; 1989 Jul; 46(1):78-81. PubMed ID: 2743709
[TBL] [Abstract][Full Text] [Related]
14. Rapid conjugation in an extremely rapid hydroxylator of debrisoquine: a case report supporting a coregulation of certain phase I and II metabolic reactions.
Bertilsson L; Aberg-Wistedt A; Dumont E; Lundström J
Ther Drug Monit; 1988; 10(2):242-4. PubMed ID: 2968008
[No Abstract] [Full Text] [Related]
15. Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism.
Alván G; Grind M; Graffner C; Sjöqvist F
Clin Pharmacol Ther; 1984 Oct; 36(4):515-9. PubMed ID: 6478737
[TBL] [Abstract][Full Text] [Related]
16. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.
Brøsen K; Klysner R; Gram LF; Otton SV; Bech P; Bertilsson L
Eur J Clin Pharmacol; 1986; 30(6):679-84. PubMed ID: 3533565
[TBL] [Abstract][Full Text] [Related]
17. Discovery of altered pharmacokinetics of CGP 15 210 G in poor hydroxylators of debrisoquine during early drug development.
Gleiter CH; Aichele G; Nilsson E; Hengen N; Antonin KH; Bieck PR
Br J Clin Pharmacol; 1985 Jul; 20(1):81-4. PubMed ID: 4027140
[TBL] [Abstract][Full Text] [Related]
18. E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation.
Mellström B; Bertilsson L; Säwe J; Schulz HU; Sjöqvist F
Clin Pharmacol Ther; 1981 Aug; 30(2):189-93. PubMed ID: 7249504
[TBL] [Abstract][Full Text] [Related]
19. Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo.
Inaba T; Tyndale RE; Mahon WA
Br J Clin Pharmacol; 1986 Aug; 22(2):199-200. PubMed ID: 3756068
[No Abstract] [Full Text] [Related]
20. Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation.
Yue QY; Svensson JO; Alm C; Sjöqvist F; Säwe J
Br J Clin Pharmacol; 1989 Dec; 28(6):639-45. PubMed ID: 2611086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
